Will disease relapse years after stopping deuterated colexitinib?

Deucravacitinib is an oral selective TYK2 inhibitor mainly used to treat moderate to severe plaque psoriasis and other autoimmune diseases. Its mechanism of action is to inhibit the IL-12, IL-23 and Type I interferon signaling pathways, thereby reducing the inflammatory response and improving skin lesions. Whether the disease will relapse after stopping the drug needs to be analyzed based on the drug's action characteristics, individual immune status, and the chronic characteristics of the disease itself.

The role of Decavatinib is to regulate immune signaling rather than to cure the disease. Psoriasis and similar autoimmune diseases are chronic and relapsing. Even if drugs are used to control symptoms for a long time, the underlying mechanism of the disease cannot be completely eliminated. Therefore, many years after stopping the drug, patients may still experience recurrence of rash, itching or scaling due to endogenous or external triggers (such as infection, mental stress, lifestyle changes).

Clinical observation shows that some patients can still maintain a long-term remission period after stopping decavatinib, which is mainly related to the self-regulation ability of the individual immune system. In patients with better immune balance and less active disease, relapse may be delayed, even years before symptoms appear. For patients with a longer course of disease or a stronger immune response, the risk of recurrence is higher. Recurrence usually manifests as original skin lesions or new skin lesions, and the severity of the condition varies from person to person.

Finally, relapse management after drug discontinuation should be combined with physician recommendations to develop an individualized plan. For patients with mild symptom recurrence, topical drugs or short-term oral treatment may be considered; for patients with significant or extensive symptom recurrence, systemic treatment may need to be restarted, including decavatinib or other targeted drugs. Regular follow-up and early intervention can help delay disease recurrence, reduce symptoms, and maintain quality of life. In summary, relapse is possible many years after drug discontinuation, but through scientific management and monitoring, disease activity can be effectively controlled.

Reference materials:https://www.drugs.com/